

Thu, 23 June 2022	Opening Session	30 minutes
09:00 – 09:30	Opening Session	
Thu, 23 June 2022	State of the Art Lecture Chairs: Sanja Kolacek (Croatia), Steffen Husby (Denmark)	30 minutes
09:30 – 10:00	Virome and microbiome interactions in childhood	Dennis Sandris Nielsen (Denmark)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

1

Thu, 23 June 2022 10:30 – 12:00	Plenary Session: Highest Scoring Abstracts Chairs: Lissy de Ridder (The Netherlands), Ulrich Baumann (Germany)	90 minutes
10:30 – 10:40	Long-term outcome of infantile and very early onset IBD: a multi-center study from the IBD Porto group of ESPGHAN	Anat Guz Mark (Israel)
10:40 – 10:50	Human Cholangiocyte Organoids as Biliary Atresia Injury and Repair Model	Orith Waisbourd-Zinman (Israel)
10:50 – 11:00	Disease course of ulcerative proctitis in children: a population based study on behalf of the SIGENP IBD group	Massimo Martinelli (Italy)
11:00 – 11:10	Effects of Butyrate Against Pediatric Obesity: the BAPO randomized-controlled trial	Serena Coppola (Italy)
11:10 – 11:20	Rare and severe complications in paediatric inflammatory bowel disease: results of 5 years of international collaboration through the PIBD-SETQuality Safety Registry	Renz Klomberg (The Netherlands)
11:20 – 11:30	Pharmacological targeting of LRH-1 prevents macrophage activation and parenteral nutrition associated cholestasis in mice	Swati Ghosh (United States)
11:30 – 11:40	One third of children undergoing colectomy due to ulcerative colitis, resume immunosuppressives or biologics post-surgery, higher than in adults - a nationwide study from the epi-IIRN	Oren Ledder (Israel)
11:40 – 11:50	A randomised, controlled trial of a Nordic, protein-reduced complementary diet: Effects on dietary intake, biomarkers and growth until 18 months of age	Ulrica Johansson (Sweden)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

2

Thu, 23 June 2022	Keynote Lecture Gastroenterology Chair: Marc Benninga (The Netherlands)	30 minutes
12:00 – 12:30	Short gut syndrome: The use of pro-adaptive agents to make the gut and patient grow	Palle Jeppesen (Denmark)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

3

Thu, 23 June 2022 14:30 – 16:30	Clinical Practice in Gastroenterology: COVID-19 in paediatric Gastroenterology Chairs: Vibeke Brix Christensen (Denmark), Marco Deganello Saccomani (Italy)	120 minutes
14:30 – 14:54	Gastrointestinal manifestations of COVID-19 in children	Ilse Broekaert (Germany)
14:54 – 15:18	COVID-19 and paediatric patients with gastrointestinal diseases under immunosuppressive treatment	Amit Assa (Israel)
15:18 – 15:42	COVID-19 and the liver	Emanuele Nicastro (Italy)
15:42 – 16:06	The effectiveness and safety of anti-COVID-19 vaccines in children and in patients with gastrointestinal diseases	Amir Ben-Tov (Israel)
16:06 – 16:30	COVID-19: The pandemic effect on the management of children with gastrointestinal diseases	Edward Gaynor (United Kingdom)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

4

Thu, 23 June 2022 14:30 – 16:30	Parallel Symposium: Management and treatment of coeliac disease Chairs: Jernej Dolinsek (Slovenia), Stine Dydensborg Sander (Denmark)	120 minutes
14:30 – 14:52	ESPGHAN position paper on the follow-up of children and adolescents with coeliac disease	Luisa Mearin (The Netherlands)
14:52 – 15:02	Abstract: Genetic risk for coeliac disease does not predict the frequency of childhood infections	Ketil Størdal (Norway)
15:02 – 15:24	The role of the gluten-challenge in the management of children with coeliac disease. How to do it today?	Alina Popp (Romania)
15:24 – 15:34	Abstract: Testing for fecal gluten immunogenic peptides: is it useful to evaluate compliance with gluten-free diet in coeliac children?	Marianna Casertano (Italy)
15:34 – 15:56	Into the future: Gluten-challenge without eating gluten	Ludvig Sollid (Norway)
15:56 – 16:06	Abstract: Inhibition of transglutaminase 2 but not microbial transglutaminase by PX12	Sebastian Stricker (Germany)
16:06 – 16:28	Non-dietary treatment of coeliac disease: Also for children (in the future)?	Detlef Schuppan (Germany)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

5

Thu, 23 June 2022 14:30 – 16:30	Parallel Symposium: Dietary patterns and their impacts in childrens' health: a path towards personalized diet? Chairs: Elvira Verduci (Italy), Nezha Mouane (Morocco)	120 minutes
14:30 – 14:52	Diet in pregnancy and its implication in the health of the offspring	Sjurdur Frodi Olsen (Denmark)
14:52 – 15:02	Abstract: Targeted individualized versus standardized preterm human milk fortification – a randomized control trial	Raghuram Mallaiah (India)
15:02 – 15:24	Dietary patterns in early life and later cardio metabolic risk	Verónica Luque (Spain)
15:24 – 15:34	Abstract: Texture matters - food pieces and developmental milestones	Maria Somaraki (France)
15:34 – 15:56	Personalized diet	Avner Leshem (Israel)
15:56 – 16:06	Abstract: Blenderised Tube Feeds vs commercial formula: how do they effect the gut microbiota of gastrostomy fed children?	Neha Chandrasekar (Australia)
16:06 – 16:30	Nordic diet	Christian Mølgaard (Denmark)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

6



Thu, 23 June 2022 14:30 – 16:30	Parallel Symposium: Intestinal failure Chairs: Susan Hill (United Kingdom), José Spolidoro (Brazil)	120 minutes
14:30 – 14:52	Intestinal failure in children: Diagnosis and genetics	Cécile Lambe (France)
14:52 – 15:02	Abstract: Real-life use of teduglutide for children with short bowel syndrome in Europe: preliminary results from the REAL TEDU Paediatric Registry	Lorenzo Norsa (Italy)
15:02 – 15:24	What is the optimal feeding in children with short bowel syndrome?	Sarah Macdonald (United Kingdom)
15:24 – 15:34	Abstract: Factors associated with weight gain on achieving enteral autonomy for children with short bowel syndrome	Virginia Chatzidaki (United Kingdom)
15:34 – 15:56	Intestinal failure: The ERNICA experience	Merit Tabbers (The Netherlands)
15:56 – 16:06	Abstract: Pre-digestion of the lipids in infant formula affects gut maturation of the preterm pig	Kamil Zaworski (Poland)
16:06 – 16:28	Novel strategies to prevent complications	Lorenzo Norsa (Italy)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

7

Thu, 23 June 2022 14:30 – 16:30	Parallel Symposium: Biliary Atresia Chairs: Piotr Czubkowski (Poland), Suporn Treepongkaruna (Thailand)	120 minutes
14:30 – 14:52	Biliary atresia: More than surgery only... steroids, CMV and novel agents	Mark Davenport (United Kingdom)
14:52 – 15:02	Abstract: The use of von-Willebrand factor and transient elastography measurements of spleen and liver as predictors of portal hypertension in children	Robert Hegarty (United Kingdom)
15:02 – 15:24	Predicting native liver injury and survival in biliary atresia: The role of serum biomarkers	Mikko P. Pakarinen (Finland)
15:24 – 15:34	Abstract: Prevalence and endoscopic features of rectal varices and colopathy in children with cirrhotic and non-cirrhotic portal hypertension	Vipul Gautam (India)
15:34 – 15:56	Portal hypertension: How to manage common and uncommon complications	Angelo Di Giorgio (Italy)
15:56 – 16:06	Abstract: Insights into mechanisms of bile duct recovery in a toxic model of biliary atresia	Orith Waisbourd-Zinman (Israel)
16:06 – 16:28	Optimising growth in biliary atresia	Sara Mancell (United Kingdom)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

8

Thu, 23 June 2022 17:00 – 18:00	Parallel Session: Gastroenterology 1 – COVID & IBD Chairs: Osvaldo Borrelli (United Kingdom), Johannes Taminiau (The Netherlands)	60 minutes
17:00 – 17:10	Spike protein produced by SARS-CoV-2 acts as an enterotoxin in an in vitro and ex-vivo model of diarrhoea	Marco Poeta (Italy)
17:10 – 17:20	COVID-19 vaccine effectiveness in inflammatory bowel disease patients on tumor-necrosis factor inhibitors: real world data from a mass-vaccination campaign	Raffi Lev-Tzion (Israel)
17:20 – 17:30	Prevention of SARS-CoV-2 infection and replication by the anti-diarrhoeal drug diosmectite: in vitro evidences in human intestinal cells	Valentina Cioffi (Italy)
17:30 – 17:40	Multispecies probiotic for the prevention of antibiotic-associated diarrhoea in children: a randomised clinical trial	Jan Lukasik (Poland)
17:40 – 17:50	Sugar Intestinal Permeability Test discriminates between Crohn's Disease and other Inflammatory Bowel Disorders, correlates with Crohn's Disease activity and predict the development of a stricturing phenotype	Giovanna Faggian (Italy)
17:50 – 18:00	Long term outcome of paediatric Crohn's disease patients with deep ulcerations at diagnosis	Monica Silvia Ronconi (France)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

9

Thu, 23 June 2022 17:00 – 18:00	Parallel Session: Gastroenterology 2 – IBD Chairs: Sibylle Koletzko (Germany), Peter John Milla (United Kingdom)	60 minutes
17:00 – 17:10	The effect of exclusive enteral nutrition on inflammation related proteins in paediatric patients with Crohn's Disease	Bernadette White (United Kingdom)
17:10 – 17:20	Predictors of response to biologics in children with ulcerative colitis: a population-based study from the epi-IIRN	Dan Turner (Israel)
17:20 – 17:30	Very Early Onset Inflammatory Bowel Disease (VEO-IBD): clinical differentiation between monogenic and non-monogenic VEO-IBD	Ujjal Poddar (India)
17:30 – 17:40	Thiopurine maintenance therapy in children with Ulcerative Colitis: A multicenter retrospective study	Firas Rinawi (Israel)
17:40 – 17:50	Psychiatric disorders in paediatric onset immune mediated inflammatory diseases – a nation-wide register study from Denmark	Sabine Jansson (Denmark)
17:50 – 18:00	The effect of compliance during exclusive enteral nutrition on faecal calprotectin in children with Crohn's disease	Shona Mckirdy (United Kingdom)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

10

Thu, 23 June 2022 17:00 – 18:00	Parallel Session: Nutrition 1 – Novelties in infant and neonatal nutrition Chairs: Miguel Saenz de Pipaón (Spain), Gitte Zachariassen (Denmark)	60 minutes
17:00 – 17:10	Improved neurodevelopmental outcomes at 5.5 years in children who received bovine milk fat globule membrane (MFGM) and bovine lactoferrin in infant formula through 12 months of age	Steven S. Wu (United States)
17:10 – 17:20	Long term impact of bovine milk fat globule membrane supplementation during infancy on executive functions at 14 years of age	Fabiola Lazarte (Peru)
17:20 – 17:30	Large, milk phospholipid-coated lipid droplets containing a mixture of dairy and vegetable lipids in infant formula and blood pressure at school age: follow up of a randomised controlled trial	Anita Hokken-Koelega (The Netherlands)
17:30 – 17:40	A novel human milk fortifier supports adequate growth in very low birth weight infants: a randomised controlled trial	Jean-Charles Picaud (France)
17:40 – 17:50	Adding bovine lactoferrin and reducing iron content in infant formula from 8 to 2 mg/L does not affect neurodevelopment at 12 month of age – a randomized controlled trial	Maria Björmsjö (Sweden)
17:50 – 18:00	The evaluation of tolerance rate and the immune tolerance acquisition in children with cow's milk allergy switching from amino acid-based formula to extensively hydrolyzed casein formula: the SDACMA project	Roberto Berni Canani (Italy)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

11

Thu, 23 June 2022 17:00 – 18:00	Parallel Session: Hepatology 1 – Around PFIC and hyperbilirubinemia Chairs: Emmanuel Gonzalès (France), Vibeke Brix Christensen (Denmark)	60 minutes
17:00 – 17:10	Efficacy and safety outcomes in patients with progressive familial intrahepatic cholestasis who had an odevixibat dose escalation: pooled results from the PEDFIC 1 and PEDFIC 2 studies	Tassos Grammatikopoulos (United Kingdom)
17:10 – 17:20	Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment	Girish Gupte (United Kingdom)
17:20 – 17:30	Maralixibat treatment response is associated with improved health-related quality of life in patients with BSEP deficiency	Douglas B. Mogul (United States)
17:30 – 17:40	Severe progressive intrahepatic cholestasis, secondary to homozygous mutation of TJP2; a single high volume pediatric liver transplant centre experience	Kishwer Kumar (Saudi Arabia)
17:40 – 17:50	Disease burden and management of Crigler-Najjar Syndrome: report of a world registry	Norman Junge (Germany)
17:50 – 18:00	Urinary coproporphyrins analysis is a potential diagnostic test of neonatal-onset Dubin-Johnson syndrome	Abdulrahman Al-Hussaini (Saudi Arabia)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

12

Thu, 23 June 2022 17:00 – 18:00	Clinical Practice in Hepatology Chairs: Aglaia Zellos (Greece), N. N.	60 minutes
17:00 – 17:20	Sclerosing cholangitis	Marianne Samyn (United Kingdom)
17:20 – 18:00	Interactive case 1	Yael Mozer Glassberg (Israel)
	Interactive case 2	Piotr Czubkowski (Poland)

Programme subject to change; version as of May 2022; all stated times correspond to Central European Summer Time (CEST)

13